EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics

Marek Jamrozik, Kamil Piska iD, Adam Bucki iD, Paulina Koczurkiewicz-Adamczyk iD, Michał Sapa, Benedykt Władyka iD, Elżbieta Pękala iD, Marcin Kołaczkowski

Molecules · 27.04.2023 · 28 (9) · 3767

DOI: 10.3390/molecules28093767 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 27.04.2023. Verfasst von Marek Jamrozik und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 St, 31-008 Cracow, Poland. Hauptthemen laut MEDLINE: Carbonyl Reductase (NADPH), Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Center, National Science Centre, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anthracycline antibiotics (ANT) are among the most widely used anticancer drugs. Unfortunately, their use is limited due to the development of drug resistance and cardiotoxicity. ANT metabolism, performed mainly by two enzymes—aldo-keto reductase 1C3 (AKR1C3) and carbonyl reductase 1 (CBR1)—is one of the proposed mechanisms generated by the described effects. In this study, we evaluated the CBR1 inhibitory properties of ASP9521, a compound already known as potent AKR1C3 inhibitor. First, we assessed the possibility of ASP9521 binding to the CBR1 catalytic site using molecular docking and molecular dynamics. The research revealed a potential binding mode of ASP9521. Moderate inhibitory activity against CBR1 was observed in studies with recombinant enzymes. Finally, we examined whether ASP9521 can improve the cytotoxic activity of daunorubicin against human lung carcinoma cell line A549 and assessed the cardioprotective properties of ASP9521 in a rat cardiomyocytes model (H9c2) against doxorubicin- and daunorubicin-induced toxicity. The addition of ASP9521 ameliorated the cytotoxic activity of daunorubicin and protected rat cardiomyocytes from the cytotoxic effect of both applied drugs. Considering the favorable bioavailability and safety profile of ASP9521, the obtained results encourage further research. Inhibition of both AKR1C3 and CBR1 may be a promising method of overcoming ANT resistance and cardiotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carbonyl Reductase (NADPH)Antineoplastic AgentsHumansRatsAnimalsMolecular Docking SimulationCardiotoxicityAnthracyclinesAntibiotics, AntineoplasticDaunorubicinAnti-Bacterial AgentsIndolesPiperidines

Stichwörter der Autor:innen

ASP9521anthracyclinescardioprotectiondockingdrug resistanceenzymatic inhibitorsmolecular dynamics

Substanzen

Carbonyl Reductase (NADPH)AnthracyclinesAntibiotics, AntineoplasticDaunorubicinAntineoplastic AgentsAnti-Bacterial Agents1-(1-((5-methoxy-1H-indol-2-yl)carbonyl)piperidin-4-yl)-2-methylpropan-2-olIndolesPiperidines

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 St, 31-008 Cracow, Poland.
  • Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 St, 31-008 Cracow, Poland.
  • Department of Analytical Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7 St, 31-007 Cracow, Poland.

ORCID-Profile: Kamil Piska, Adam Bucki, Paulina Koczurkiewicz-Adamczyk, Benedykt Władyka, Elżbieta Pękala

Förderung

  • National Science Center
  • National Science Centre, Poland

Zitieren

APA

Jamrozik, M., Piska, K., Bucki, A., Koczurkiewicz-Adamczyk, P., Sapa, M., Władyka, B., Pękala, E., & Kołaczkowski, M. (2023). In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics. Molecules, 28(9), 3767. https://doi.org/10.3390/molecules28093767

Vancouver

Jamrozik M, Piska K, Bucki A, Koczurkiewicz-Adamczyk P, Sapa M, Władyka B, et al. In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics. Molecules. 2023;28(9):3767. doi:10.3390/molecules28093767

BibTeX
@article{Jamrozik2023,
  author = {Jamrozik, Marek and Piska, Kamil and Bucki, Adam and Koczurkiewicz-Adamczyk, Paulina and Sapa, Michał and Władyka, Benedykt and Pękala, Elżbieta and Kołaczkowski, Marcin},
  title = {In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {9},
  pages = {3767},
  doi = {10.3390/molecules28093767}
}
Kostenlos starten →